
|Videos|March 11, 2022
Dr. Oh gives overview of oligometastatic prostate cancer and emergent therapies
Author(s)Urology Times staff
“We have new therapies, both AR-targeted therapies, as well as the use of SBRT, or targeted radiotherapy, that have changed the landscape,” says William K. Oh, MD.
Advertisement
In this video, William K. Oh, MD, discusses why oligometastatic prostate cancer is a “hot topic” in urology right now, and what therapies are expected to emerge in the near future to help manage this complex disease state. These concepts stem from Oh’s presentation, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










